American Association for Cancer Research

SHERPA: Unknown

People

  1. Solit
    Solit
  2. Ladanyi
    Ladanyi
  3. Rosen
    Rosen
  4. Hudis
    Hudis
  5. Scher
    Scher
  6. Baselga
    Baselga
  7. Berger
    Berger
  8. Norton
    Norton
  9. Reis-Filho
    Reis-Filho
  10. Cordon-Cardo
    Cordon-Cardo

Groups

  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1641)
  4. Sloan Kettering Institute Faculty (788)
  5. Sloan Kettering Institute Postdocs (787)
  6. Department of Pathology and Laboratory Medicine (744)
  7. Human Oncology and Pathogenesis Program (687)
  8. Surgery (647)
  9. Breast Medicine Service (611)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (589)
Search Within
Formats
  1. Journal Article (2035)
  2. Meeting Abstract (2011)
  3. Editorial (49)
  4. Review (29)
  5. Conference Paper (14)
  6. Correspondence (6)
  7. Miscellaneous (4)
  8. Guidelines (1)
Groups
  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1641)
  4. Sloan Kettering Institute Faculty (788)
  5. Sloan Kettering Institute Postdocs (787)
  6. Department of Pathology and Laboratory Medicine (744)

More Groups

People
  1. David Solit (176)
  2. Marc Ladanyi (158)
  3. Neal Rosen (142)
  4. Clifford Hudis (141)
  5. Howard Scher (139)
  6. Jose Baselga (138)

More People

Years
  1. 2025 (51)
  2. 2024 (75)
  3. 2023 (79)
  4. 2022 (266)
  5. 2021 (235)
  6. 2020 (272)

More Years

Publications
  1. Cancer Research (2704)
  2. Clinical Cancer Research (1445)

Results (4149)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Meeting Abstract

    Olivera, M.; Jhaveri, K.; Juric, D.; Bedard, P. L.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Emerging from COVID-19 pandemic: Provider perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancer
    Meeting Abstract

    Park, K. U.; Gregory, M. E.; Lustberg, M. B.; Bazan, J. G.; Shen, C.; Rosenberg, S. M.; Blinder, V. S.; Sharma, P.; Pusztai, L.; Partridge, A. H.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer
    Meeting Abstract

    Rosen, E. Y.; Italiano, A.; Juric, D.; Reeves, J. A.; Dima, L.; Brega, N.; Drilon, A.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Early intervention for and management of alpelisib (ALP)-induced hyperglycemia: Case studies from the phase III SOLAR-1 trial
    Meeting Abstract

    Mayer, I.; Farooki, A.; Rugo, H. S.; Iwata, H.; Ciruelos, E.; Campone, M.; Loibl, S.; Conte, P.; Juric, D.; Ghaznawi, F.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase Ib trial of fulvestrant + CDK4/6 inhibitor (CDK4/6i) palbociclib + pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in FGFR-amplified/ ER+/ HER2-negative metastatic breast cancer (MBC)
    Meeting Abstract

    Mayer, I. A.; Haley, B. B.; Abramson, V. G.; Brufsky, A.; Rexer, B.; Stringer-Reasor, E.; Jhaveri, K. L.; Sanders, M.; Ericsson-Gonzalez, P. I.; Ye, F.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Patient-reported outcomes from the phase III IMpassion031 trial of neoadjuvant atezolizumab + chemotherapy in early triple-negative breast cancer
    Meeting Abstract

    Mittendorf, E.; Harbeck, N.; Zhang, H.; Saji, S.; Jung, K. H.; Patel, S.; Patel, S.; Duc, A. N.; Liste-Hermoso, M.; Chui, S. Y.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer
    Meeting Abstract

    Modi, S.; Saura, C.; Yamashita, T.; Park, Y. H.; Kim, S. B.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)
    Meeting Abstract

    Krop, I.; Yonemori, K.; Takahashi, S.; Inoue, K.; Nakayama, T.; Iwata, H.; Toyama, T.; Yamamoto, Y.; Takahashi, M.; Osaki, A.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Trends in genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2013-2017
    Meeting Abstract

    Kurian, A. W.; Morrow, M.; Katz, S.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Phase 1/2 clinical trial of a topical submicron particle paclitaxel (SOR007) for the treatment of cutaneous metastases
    Meeting Abstract

    Lacouture, M. E.; Lang, J. E.; Chawla, S.; Goldfarb, S.; Markova, A.; Pan, A.; Cavanna-Mast, R. M.; Mast, P.; Savoie, C.; diZerega, G.
    Cancer Research (2021)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: